- Advanced search
- Immuno Portal
- Malaria Portal
Abbreviated name: IB-MECA
Synonyms: CF 101 | CF101 | N(6)-ibamu
Compound class: Synthetic organic
Comment: Piclidenoson is a selective agonist of the adenosine A3 receptor. It has anti-inflammatory action which is being investigated for translation to the clinic .
Early investigations revealed anti-cancer effects [1,5,12].
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Piclidenoson (CF101) is being evaluated in a number of clinical trials, as a potential therapy for several autoimmune-inflammatory disorders (rheumatoid arthritis, Phase III, NCT02647762 ; plaque psoriasis, Phase II ; uveitis Phase II) and glaucoma (Phase II, NCT01033422 ).|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT01033422||Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure||Phase 2 Interventional||Can-Fite BioPharma|
|NCT02647762||CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis||Phase 3 Interventional||Can-Fite BioPharma|